

STELLINGEN BEHOREND BIJ HET PROEFSCHRIFT:

**Altered Gene & MiRNA Regulation in
Pediatric Acute Myeloid Leukemia**

Jenny E. Katsman-Kuipers

1. High expression of *IGSF4* in pediatric AML with *MLL*-rearrangements and t(9;11)(p22;q23) is explained by promoter demethylation. (*this thesis*)
2. Differences in miRNA expression reflect the genetic heterogeneity of pediatric AML. (*this thesis*)
3. *RUNX1* mutations occur rarely in *de novo* pediatric AML and seem associated with poor outcome. (*this thesis*)
4. Epigenetic events like miRNA deregulation and DNA methylation contribute to leukemogenesis in pediatric AML, thereby providing promising candidates for future research towards targeted therapy. (*this thesis*)
5. MiR-9 is a tumor suppressor in pediatric AML characterized by t(8;21). (*this thesis*)
6. Only international collaboration will provide adequate numbers of pediatric AML patients to power trial questions investigating new targeted therapies within subgroups. (*U. Creutzig, Blood 2012*)
7. The good, what particular men may do separately in relieving the sick, is small, compared with what they may do collectively. (*B. Franklin, 1751*)
8. We need to view data as a community resource, much like a shared park, rather than as personal property. (*J. Drazen, NEJM 2015*)
9. The good physician treats the disease; the great physician treats the patient who has the disease. (*William Osler*)
10. Elke Nederlander moet vrij zijn om zijn eigen arts te kiezen. (*n.a.v. aanpassing artikel 13 zorgverzekeringswet, december 2014*)
11. It takes courage to grow up and turn out to be who you really are. (*E.E. Cummings*)